AB Science is developing its lead compound masitinib in veterinary medicine. Since 2008 in Europe and since 2010 in the USA, masitinib is registered in a canine cancer called mast cell tumor, the most common cutaneous cancer in dogs. The drug is marketed by AB Science under the brand Masivet® in Europe and Kinavet in the…
Prostate cancer is one of the most common types of cancer in men. Masitinib is currently investigated in first-line metastatic castrate-resistant prostate cancer (mCRPC). This patient population consists of patients who have disease progression despite androgen depletion therapy (castration) treatment. There is still a need for more effective first-line treatment of mCRPC since recent therapies…
The severity of asthma can be graded from mild intermittent disease, with little impact on everyday life, through to severe disease with permanent symptoms and serious limitation of normal activities. Data suggests that mast cells are involved in allergic and anaphylactic reactions, playing an important role in hypersensitivity and inflammatory processes of the disease and…
AB8939 is a new small-molecule drug that binds to tubulin and induces a rapid destabilisation of microtubules. Through disorganisation of microtubules, AB8939 is able to induce the apoptosis at nanomolar concentration of a wide panel of tumor cell lines, in particular hematopoietic tumor cell lines (i.e. cancers that affect the blood and lymph system) and…